Symbols / ACHV $5.10 +6.03% Achieve Life Sciences, Inc.
ACHV Chart
About
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 271.52M |
| Enterprise Value | 250.07M | Income | -54.65M | Sales | — |
| Book/sh | 0.40 | Cash/sh | 0.68 | Dividend Yield | — |
| Payout | 0.00% | Employees | 28 | IPO | — |
| P/E | — | Forward P/E | -4.91 | PEG | 17.68 |
| P/S | — | P/B | 12.62 | P/C | — |
| EV/EBITDA | -4.58 | EV/Sales | — | Quick Ratio | 4.01 |
| Current Ratio | 4.39 | Debt/Eq | 69.50 | LT Debt/Eq | — |
| EPS (ttm) | -1.25 | EPS next Y | -1.04 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-12 | ROA | -85.30% |
| ROE | -257.67% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 53.24M |
| Shs Float | 47.13M | Short Float | 15.61% | Short Ratio | 9.67 |
| Short Interest | — | 52W High | 6.03 | 52W Low | 1.96 |
| Beta | 1.96 | Avg Volume | 945.60K | Volume | 4.21M |
| Target Price | $14.75 | Recom | Strong_buy | Prev Close | $4.81 |
| Price | $5.10 | Change | 6.03% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2026-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-11-25 | init | Citizens | — → Market Outperform | $19 |
| 2025-08-21 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2024-11-14 | init | Rodman & Renshaw | — → Buy | $12 |
| 2024-08-15 | reit | Oppenheimer | Outperform → Outperform | $11 |
| 2024-05-13 | main | Oppenheimer | Outperform → Outperform | $11 |
| 2024-04-17 | init | JonesTrading | — → Buy | $20 |
| 2024-04-01 | reit | Oppenheimer | Outperform → Outperform | $18 |
| 2024-03-05 | main | Lake Street | Buy → Buy | $11 |
| 2023-12-12 | main | Oppenheimer | Outperform → Outperform | $18 |
| 2023-05-31 | main | Lake Street | Buy → Buy | $19 |
| 2023-05-10 | main | Lake Street | Buy → Buy | $22 |
| 2023-03-17 | reit | Oppenheimer | — → Outperform | $17 |
| 2022-11-16 | main | Maxim Group | — → Buy | $8 |
| 2021-10-04 | init | Alliance Global Partners | — → Buy | $25 |
| 2021-06-23 | init | Oppenheimer | — → Outperform | $23 |
| 2020-09-17 | init | Lake Street | — → Buy | $30 |
| 2020-02-25 | init | HC Wainwright & Co. | — → Buy | $2 |
| 2019-06-14 | init | Maxim Group | — → Buy | $6 |
- Nicotine-dependence drug moves to Ohio production ahead of FDA refiling - Stock Titan Wed, 15 Apr 2026 12
- ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits hu, 16 Apr 2026 17
- ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - MSN Sat, 18 Apr 2026 23
- ACHV Stock Gains Focus As Cytisinicline Data And NDA Timeline Firm Up - timothysykes.com hu, 16 Apr 2026 13
- Achieve Life Sciences: The Recent Sell-Off Skews The Outcomes (NASDAQ:ACHV) - Seeking Alpha Wed, 01 Apr 2026 07
- Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory - Yahoo Finance Mon, 02 Feb 2026 08
- Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright - MarketBeat hu, 16 Apr 2026 12
- ACHIEVE LIFE SCIENCES ($ACHV) Releases Q4 2025 Earnings | ACHV Stock News - Quiver Quantitative ue, 24 Mar 2026 07
- Achieve Life Sciences (ACHV) Secures $354M Through Private Place - GuruFocus Fri, 17 Apr 2026 03
- Achieve secures $180M now, with $174M more tied to FDA approval - Stock Titan hu, 16 Apr 2026 12
- Achieve Life Sciences, Inc. (NASDAQ:ACHV) Is Expected To Breakeven In The Near Future - Yahoo Finance Sat, 17 Jan 2026 08
- ACHV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus hu, 16 Apr 2026 14
- New Analyst Forecast: $ACHV Given $19.0 Price Target | ACHV Stock News - Quiver Quantitative ue, 25 Nov 2025 08
- Achieve, pursuing a new nicotine treatment, picks physician as CEO - Stock Titan hu, 16 Apr 2026 12
- $354M funding and new CEO reshape Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan hu, 16 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
54.88
+40.47%
|
39.07
+43.37%
|
27.25
-33.21%
|
40.80
|
| Research And Development |
|
23.00
+0.79%
|
22.82
+44.28%
|
15.81
-47.42%
|
30.08
|
| Selling General And Administration |
|
31.88
+96.17%
|
16.25
+42.11%
|
11.44
+6.66%
|
10.72
|
| General And Administrative Expense |
|
31.88
+96.17%
|
16.25
+42.11%
|
11.44
+6.66%
|
10.72
|
| Other Gand A |
|
31.88
+96.17%
|
16.25
+42.11%
|
11.44
+6.66%
|
10.72
|
| Total Expenses |
|
54.88
+40.47%
|
39.07
+43.37%
|
27.25
-33.21%
|
40.80
|
| Operating Income |
|
-54.88
-40.47%
|
-39.07
-43.37%
|
-27.25
+33.21%
|
-40.80
|
| EBITDA |
|
-53.60
-43.25%
|
-37.42
-39.96%
|
-26.73
+33.70%
|
-40.33
|
| Normalized EBITDA |
|
-53.19
-45.68%
|
-36.51
-39.33%
|
-26.21
+35.01%
|
-40.33
|
| Reconciled Depreciation |
|
0.23
-0.44%
|
0.23
+0.44%
|
0.23
-3.39%
|
0.24
|
| EBIT |
|
-53.83
-42.98%
|
-37.65
-39.63%
|
-26.96
+33.53%
|
-40.56
|
| Total Unusual Items |
|
-0.41
+54.87%
|
-0.90
-71.21%
|
-0.53
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-0.41
+54.87%
|
-0.90
-71.21%
|
-0.53
|
0.00
|
| Special Income Charges |
|
-0.41
+54.87%
|
-0.90
-71.21%
|
-0.53
|
0.00
|
| Other Special Charges |
|
—
|
0.28
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
0.41
-34.30%
|
0.62
+17.61%
|
0.53
|
0.00
|
| Net Income |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Pretax Income |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Net Non Operating Interest Income Expense |
|
0.68
+284.09%
|
0.18
+108.68%
|
-2.03
-27.55%
|
-1.59
|
| Interest Expense Non Operating |
|
0.82
-62.43%
|
2.18
-23.59%
|
2.85
+59.47%
|
1.79
|
| Net Interest Income |
|
0.68
+284.09%
|
0.18
+108.68%
|
-2.03
-27.55%
|
-1.59
|
| Interest Expense |
|
0.82
-62.43%
|
2.18
-23.59%
|
2.85
+59.47%
|
1.79
|
| Interest Income Non Operating |
|
1.50
-36.54%
|
2.36
+185.58%
|
0.82
+314.57%
|
0.20
|
| Interest Income |
|
1.50
-36.54%
|
2.36
+185.58%
|
0.82
+314.57%
|
0.20
|
| Other Income Expense |
|
-0.44
+52.46%
|
-0.93
-73.93%
|
-0.54
-1442.50%
|
0.04
|
| Other Non Operating Income Expenses |
|
-0.04
-20.00%
|
-0.03
-233.33%
|
-0.01
-122.50%
|
0.04
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Net Income From Continuing Operation Net Minority Interest |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Net Income From Continuing And Discontinued Operation |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Net Income Continuous Operations |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Normalized Income |
|
-54.24
-39.35%
|
-38.92
-32.90%
|
-29.29
+30.85%
|
-42.35
|
| Net Income Common Stockholders |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Diluted EPS |
|
-1.25
-0.81%
|
-1.24
+17.33%
|
-1.50
+62.50%
|
-4.00
|
| Basic EPS |
|
-1.25
-0.81%
|
-1.24
+17.33%
|
-1.50
+62.50%
|
-4.00
|
| Basic Average Shares |
|
43.59
+35.93%
|
32.07
+61.75%
|
19.83
+87.17%
|
10.59
|
| Diluted Average Shares |
|
43.59
+35.93%
|
32.07
+61.75%
|
19.83
+87.17%
|
10.59
|
| Diluted NI Availto Com Stockholders |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
41.79
+8.17%
|
38.63
+99.44%
|
19.37
-35.37%
|
29.97
|
| Current Assets |
|
39.89
+9.38%
|
36.47
+114.74%
|
16.98
-37.86%
|
27.33
|
| Cash Cash Equivalents And Short Term Investments |
|
36.38
+5.95%
|
34.34
+121.61%
|
15.50
-37.32%
|
24.72
|
| Cash And Cash Equivalents |
|
20.91
+64.21%
|
12.73
-17.83%
|
15.50
-37.32%
|
24.72
|
| Cash Equivalents |
|
20.27
+67.04%
|
12.13
-14.85%
|
14.25
-37.37%
|
22.76
|
| Cash Financial |
|
0.64
+6.86%
|
0.60
-51.93%
|
1.24
-36.69%
|
1.97
|
| Other Short Term Investments |
|
15.47
-28.38%
|
21.61
|
0.00
|
—
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.11
+5.71%
|
0.10
|
| Other Receivables |
|
—
|
—
|
0.11
+5.71%
|
0.10
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.02
+0.00%
|
0.02
-60.00%
|
0.05
+0.00%
|
0.05
|
| Other Current Assets |
|
3.48
+65.40%
|
2.11
+59.02%
|
1.32
-46.01%
|
2.45
|
| Total Non Current Assets |
|
1.90
-12.23%
|
2.17
-9.33%
|
2.39
-9.54%
|
2.64
|
| Net PPE |
|
0.06
-46.22%
|
0.12
+80.30%
|
0.07
-46.34%
|
0.12
|
| Gross PPE |
|
0.06
-46.22%
|
0.12
+80.30%
|
0.07
-46.34%
|
0.12
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
-0.30
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
0.26
|
| Other Properties |
|
0.06
-46.22%
|
0.12
+80.30%
|
0.07
-46.34%
|
0.12
|
| Leases |
|
—
|
—
|
—
|
0.03
|
| Goodwill And Other Intangible Assets |
|
1.78
-11.11%
|
2.01
-10.00%
|
2.23
-9.01%
|
2.45
|
| Goodwill |
|
1.03
+0.00%
|
1.03
+0.00%
|
1.03
+0.00%
|
1.03
|
| Other Intangible Assets |
|
0.75
-22.90%
|
0.97
-18.63%
|
1.20
-15.59%
|
1.42
|
| Other Non Current Assets |
|
0.05
+33.33%
|
0.04
-57.61%
|
0.09
+39.39%
|
0.07
|
| Total Liabilities Net Minority Interest |
|
20.27
+14.31%
|
17.73
-14.82%
|
20.82
-3.92%
|
21.67
|
| Current Liabilities |
|
9.08
+35.92%
|
6.68
-67.90%
|
20.81
-3.64%
|
21.60
|
| Payables And Accrued Expenses |
|
1.84
-48.92%
|
3.60
+188.23%
|
1.25
-67.06%
|
3.79
|
| Payables |
|
0.87
-55.54%
|
1.95
+215.53%
|
0.62
-62.77%
|
1.66
|
| Accounts Payable |
|
0.87
-55.54%
|
1.95
+215.53%
|
0.62
-62.77%
|
1.66
|
| Current Accrued Expenses |
|
0.97
-41.09%
|
1.65
+161.49%
|
0.63
-70.40%
|
2.13
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.92
-36.54%
|
3.03
+30.98%
|
2.31
+37.72%
|
1.68
|
| Current Debt And Capital Lease Obligation |
|
3.77
+6745.45%
|
0.06
-99.67%
|
16.73
+3.70%
|
16.13
|
| Current Debt |
|
3.70
|
—
|
16.66
+3.68%
|
16.07
|
| Other Current Borrowings |
|
3.70
|
—
|
16.66
+3.68%
|
16.07
|
| Current Capital Lease Obligation |
|
0.06
+10.91%
|
0.06
-12.70%
|
0.06
+8.62%
|
0.06
|
| Other Current Liabilities |
|
1.56
|
—
|
0.53
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
11.19
+1.25%
|
11.05
+184100.00%
|
0.01
-91.30%
|
0.07
|
| Long Term Debt And Capital Lease Obligation |
|
11.19
+13.00%
|
9.90
+164950.00%
|
0.01
-91.30%
|
0.07
|
| Long Term Debt |
|
11.19
+13.70%
|
9.84
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.01
-92.42%
|
0.07
+1000.00%
|
0.01
-91.30%
|
0.07
|
| Other Non Current Liabilities |
|
—
|
1.15
|
—
|
—
|
| Stockholders Equity |
|
21.52
+2.96%
|
20.90
+1543.30%
|
-1.45
-117.44%
|
8.30
|
| Common Stock Equity |
|
21.52
+2.96%
|
20.90
+1543.30%
|
-1.45
-117.44%
|
8.30
|
| Capital Stock |
|
0.12
+17.48%
|
0.10
+14.44%
|
0.09
+3.45%
|
0.09
|
| Common Stock |
|
0.12
+17.48%
|
0.10
+14.44%
|
0.09
+3.45%
|
0.09
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
53.23
+53.48%
|
34.69
+63.87%
|
21.17
+18.26%
|
17.90
|
| Ordinary Shares Number |
|
53.23
+53.48%
|
34.69
+63.87%
|
21.17
+18.26%
|
17.90
|
| Additional Paid In Capital |
|
281.61
+24.42%
|
226.34
+37.84%
|
164.21
+13.92%
|
144.15
|
| Retained Earnings |
|
-260.23
-26.58%
|
-205.58
-24.03%
|
-165.75
-21.93%
|
-135.94
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
-67.74%
|
0.03
+675.00%
|
0.00
+0.00%
|
0.00
|
| Other Equity Adjustments |
|
0.01
-67.74%
|
0.03
+675.00%
|
0.00
+0.00%
|
0.00
|
| Total Equity Gross Minority Interest |
|
21.52
+2.96%
|
20.90
+1543.30%
|
-1.45
-117.44%
|
8.30
|
| Total Capitalization |
|
32.70
+6.40%
|
30.74
+2222.65%
|
-1.45
-117.44%
|
8.30
|
| Working Capital |
|
30.81
+3.43%
|
29.79
+877.47%
|
-3.83
-166.85%
|
5.73
|
| Invested Capital |
|
36.41
+18.45%
|
30.74
+102.02%
|
15.21
-37.58%
|
24.37
|
| Total Debt |
|
14.96
+50.18%
|
9.96
-40.48%
|
16.73
+3.29%
|
16.20
|
| Net Debt |
|
—
|
—
|
1.17
|
—
|
| Capital Lease Obligations |
|
0.07
-45.45%
|
0.12
+75.36%
|
0.07
-45.67%
|
0.13
|
| Net Tangible Assets |
|
19.73
+4.46%
|
18.89
+613.48%
|
-3.68
-162.88%
|
5.85
|
| Tangible Book Value |
|
19.73
+4.46%
|
18.89
+613.48%
|
-3.68
-162.88%
|
5.85
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-49.47
-66.16%
|
-29.77
-21.61%
|
-24.48
+34.84%
|
-37.57
|
| Cash Flow From Continuing Operating Activities |
|
-49.47
-66.16%
|
-29.77
-21.61%
|
-24.48
+34.84%
|
-37.57
|
| Net Income From Continuing Operations |
|
-54.65
-37.21%
|
-39.83
-33.58%
|
-29.82
+29.60%
|
-42.35
|
| Depreciation Amortization Depletion |
|
0.23
-0.44%
|
0.23
+0.44%
|
0.23
-3.39%
|
0.24
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Amortization Cash Flow |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
0.23
-0.44%
|
0.23
+0.44%
|
0.23
-3.39%
|
0.24
|
| Amortization Of Intangibles |
|
—
|
—
|
—
|
—
|
| Other Non Cash Items |
|
0.46
-74.56%
|
1.81
-26.11%
|
2.45
+104.60%
|
1.20
|
| Stock Based Compensation |
|
8.76
+64.53%
|
5.33
+54.84%
|
3.44
+5.17%
|
3.27
|
| Operating Gains Losses |
|
—
|
0.28
|
—
|
—
|
| Change In Working Capital |
|
-4.27
-276.87%
|
2.41
+410.03%
|
-0.78
-1084.81%
|
0.08
|
| Change In Receivables |
|
0.00
-100.00%
|
0.11
+1950.00%
|
-0.01
-112.50%
|
0.05
|
| Change In Prepaid Assets |
|
-1.40
-82.61%
|
-0.77
-165.05%
|
1.18
+226.32%
|
-0.93
|
| Change In Payables And Accrued Expense |
|
-2.87
-193.54%
|
3.07
+262.28%
|
-1.89
-295.45%
|
0.97
|
| Change In Accrued Expense |
|
-1.79
-202.94%
|
1.74
+304.60%
|
-0.85
-604.76%
|
0.17
|
| Change In Payable |
|
-1.08
-181.31%
|
1.33
+227.83%
|
-1.04
-230.41%
|
0.80
|
| Change In Account Payable |
|
-1.08
-181.31%
|
1.33
+227.83%
|
-1.04
-230.41%
|
0.80
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.26
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.00
+98.28%
|
-0.06
-1060.00%
|
-0.01
|
| Investing Cash Flow |
|
6.11
+128.32%
|
-21.58
-102661.90%
|
-0.02
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
6.11
+128.32%
|
-21.58
-102661.90%
|
-0.02
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.00
|
0.00
+100.00%
|
-0.02
|
0.00
|
| Purchase Of PPE |
|
-0.00
|
0.00
+100.00%
|
-0.02
|
0.00
|
| Capital Expenditure |
|
-0.00
|
—
|
-0.02
|
—
|
| Net Investment Purchase And Sale |
|
6.12
+128.34%
|
-21.58
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-24.75
+48.31%
|
-47.89
|
0.00
|
0.00
|
| Sale Of Investment |
|
30.87
+17.35%
|
26.31
|
0.00
|
0.00
|
| Financing Cash Flow |
|
51.53
+6.18%
|
48.53
+217.63%
|
15.28
-20.90%
|
19.32
|
| Cash Flow From Continuing Financing Activities |
|
51.53
+6.18%
|
48.53
+217.63%
|
15.28
-20.90%
|
19.32
|
| Net Issuance Payments Of Debt |
|
5.00
+160.28%
|
-8.29
|
0.00
|
0.00
|
| Issuance Of Debt |
|
5.00
-49.05%
|
9.81
|
0.00
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-18.11
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
5.00
-49.05%
|
9.81
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-18.11
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
5.00
+160.28%
|
-8.29
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
45.14
-19.50%
|
56.08
+267.21%
|
15.27
-20.51%
|
19.21
|
| Common Stock Payments |
|
0.00
|
0.00
+100.00%
|
-0.03
|
—
|
| Repurchase Of Capital Stock |
|
0.00
|
0.00
+100.00%
|
-0.03
|
—
|
| Proceeds From Stock Option Exercised |
|
1.39
+61.05%
|
0.86
+278.85%
|
0.23
+51.33%
|
0.15
|
| Net Other Financing Charges |
|
—
|
-0.11
+48.18%
|
-0.22
-368.09%
|
-0.05
|
| Changes In Cash |
|
8.17
+389.51%
|
-2.82
+69.39%
|
-9.22
+49.48%
|
-18.25
|
| Effect Of Exchange Rate Changes |
|
0.00
|
0.00
+100.00%
|
-0.00
-200.00%
|
0.00
|
| Beginning Cash Position |
|
12.77
-18.10%
|
15.60
-37.17%
|
24.82
-42.37%
|
43.07
|
| End Cash Position |
|
20.95
+64.01%
|
12.77
-18.10%
|
15.60
-37.17%
|
24.82
|
| Free Cash Flow |
|
-49.47
-66.17%
|
-29.77
-21.51%
|
-24.50
+34.79%
|
-37.57
|
| Common Stock Issuance |
|
45.14
-19.50%
|
56.08
+266.49%
|
15.30
-20.36%
|
19.21
|
| Issuance Of Capital Stock |
|
45.14
-19.50%
|
56.08
+266.49%
|
15.30
-20.36%
|
19.21
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-16 View
- 10-K2026-03-24 View
- 8-K2026-03-24 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42025-12-08 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 8-K2025-10-07 View
- 42025-10-03 View
- 42025-09-22 View
- 42025-09-22 View
- 8-K2025-09-11 View
- 42025-09-08 View
- 42025-09-08 View
- 42025-09-08 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|